Andrew Plump, MD, PhD, is the Chief Medical and Scientific Officer of Takeda Pharmaceutical and a member of its Board of Directors. His approach toward drug research and development is “bench to bedside to bench” learning. He is a translational physician-scientist with deep knowledge in biomedical research, experimental medicine, early development, genomics and biomarkers, and contributions in neuroscience, cardiovascular and metabolic diseases.
Currently, Dr. Plump leads a world-class R&D organization focused on gastroenterology, neuroscience and oncology, and vaccines. The Takeda R&D organization is committed to delivering innovative solutions that address unmet needs. Prior to Takeda, Dr. Plump served as Senior Vice President, Research & Translational Medicine, Deputy to the President of R&D at Sanofi, and Vice President, Worldwide Cardiovascular Research Head at Merck.
Dr. Plump received his MD from UCSF and his PhD from Rockefeller University. He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Dr. Plump trained as a postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an Adjunct Clinical Instructor in the Department of Medical Genetics. Dr. Plump serves on several committees and external boards for organizations including: The Sarnoff Cardiovascular Research Foundation, The University of Bristol Integrative Epidemiology Unit, and the PhRMA Foundation.